Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders.
United Kingdom
Joined May 2020
- Tweets1.4K
- Following185
- Followers8.4K
- Likes909
In indirect cross-trial comparisons, SVN-001’s reported reduction was above figures reported for:
• Vivitrol — 25%
• Pemvidutide — 35%
• Semaglutide — 46%
SVN-001 followed a defined 4-week treatment course.
Comparisons are across separate trials and do not establish comparative efficacy.
A second analysis found significant reductions in craving and rumination at three months, adding to our understanding of how SVN-001 may work.
$SVNS
PTSD affects an estimated 15.8m people across the U.S., UK, EU4 & Japan.
Strategic interest is growing: Otsuka recently acquired PTSD-focused Transcend Therapeutics for up to US$1.225bn.
£1.3m raised. A new UK institutional investor. A sector in strategic motion.
$SVNS has conditionally raised £1.3m to advance defined milestones across our priority CNS programmes.
Here’s what the new capital supports 👇
SVN-015 | Proprietary pipeline
Progressing alongside the U.S. National Institute on Drug Abuse (NIDA), following its selection for further evaluation under NIDA’s Addiction Treatment Discovery Program.
The financing comes at a time of renewed strategic appetite for neuropsychiatry assets, with significant recent transactions involving J&J, AbbVie, Otsuka and Eli Lilly.
New institutional capital. Defined value inflection points. Growing sector momentum.
Turner Pope acted as sole bookrunner
🔗solvonis.com/news/solvonis-r…
$SVNS
@Solvonis is advancing its U.S. investor-engagement strategy.
CEO Anthony Tennyson will present at the @WTR_Research Virtual Insights Conference, 22–23 Sept, covering our CNS pipeline, value drivers and U.S. strategy, alongside investor meetings.
$SVNS #CNS #Biotech
Independent validation matters.
SVN-015 has progressed into further #NIDA-funded studies following encouraging initial screening.
Next:
• Confirmatory transporter studies
• In vivo pharmacology
• Further selectivity assessment
Another milestone for our proprietary #CNS discovery pipeline.
🔗solvonis.com/news/svn-015-ad…
$SVNS
#Biotech #DrugDiscovery #CNSSAP
Three trends are reshaping neuropsychiatry:
✓ Clearer regulatory pathways
✓ Growing clinical validation
✓ Increasing strategic investment
Together, they are creating a stronger foundation for innovation across #addiction and #mental_health.
We're excited to be part of that journey.
#Neuropsychiatry #Biotech #CNS #DrugDevelopment $SVNS
Big Pharma's renewed interest in #neuropsychiatry validates the opportunity.
For @Solvonis, long-term value creation comes from building a portfolio with:
• Differentiated science
• Clinical & discovery-stage CNS assets
• Clear development pathways
Execution—not momentum—will define the next generation of CNS companies.
$SVNS #Biotech #CNS #Neuropsychiatry
Big pharma is moving back into neuropsych
@EliLillyandCo / @ataibeckley, @OtsukaUS / Transcend & @AbbVie / @GilgameshRX = $6.2bn in acquisitions across psychedelic & neuropsych
@Solvonis is building a CNS pipeline in addiction & psychiatry
$SVNS #CNS #Biotech #Neuropsychiatry
🤖 Made with AI
Solvonis Therapeutics plc retweeted
😃Growing understanding of the role of serotonin and dopamine in addictions: implications for new treatments
✏️David Nutt at @Solvonis
Read here: tinyurl.com/23kdy8hr
@Solvonis is building a focused CNS therapeutics portfolio in #addiction & #psychiatry
Our R&D strategy combines
• repurposing-led clinical dev.
• proprietary CNS drug discovery
Clinical-stage AUD programs + proprietary preclinical assets
Follow for updates
$SVNS #CNS
Solvonis Therapeutics plc retweeted
INITIATION OF COVERAGE
We have initiated coverage on Solvonis Therapeutics PLC (LSE: $SVNS), a clinical-stage biotechnology company developing acute intervention therapies for high-burden central nervous system (CNS) disorders.
• Our report explores Solvonis' differentiated approach to treating alcohol use disorder through ketamine-based therapies designed to deliver durable outcomes rather than chronic maintenance treatment.
• We examine the company's clinical pipeline, including its Phase 3 and Phase 2b programs, AI-enabled drug discovery platform, and capital-efficient development strategy.
• We also highlight the key clinical, regulatory, and corporate milestones that could shape the company's progress over the coming years.
• Don't miss WTR analyst Robert Sassoon's Quick Take video, where he walks through the key highlights of the Solvonis investment story and our initiation of coverage.
Read Robert Sassoon's full Initiation of Coverage report to learn more about the investment thesis and upcoming catalysts.
watertowerresearch.com/doc?d…
$SVNS @Solvonis #InitiationOfCoverage #Biotech #CNS #AlcoholUseDisorder #MentalHealth #DrugDevelopment #SmallCap #Stocks #WaterTowerResearch
